B+
Bull case
25%
Probability
Target price
$5.80
-3.8% vs current
IMDX
Insight Molecular DiagnosticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.20
-46.9% vs current
B-
Bear case
25%
Probability
Target price
$2.00
-66.8% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+6.1
Score
AI commentary
Current sentiment reads as cautious monitoring rather than high-conviction bullishness. Primary sources support a real regulatory catalyst and a better liquidity position after the February 2026 raise, but deterministic signals remain negative and uncertainty is still elevated because the story hinges on FDA review and first proof of commercialization instead of established revenue durability.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystRunway and loss-profile digestion after Q4/FY2025 results and February financingHigh impact
The company reported 2025 revenue of $4.1 million, 2025 net loss of $50.2 million, and year-end cash of $11.6 million, then raised about $24.6 million net in February 2026; the setup improves near-term survival versus the prior year but still leaves investors focused on burn and commercialization pacing rather than current earnings power [#8-K-2026-03-26] [#10-K-2026-03-26] [#PR-2026-03-26].
2026-08-22eventFDA review outcome for GraftAssureDx De Novo submissionHigh impact
Management said it submitted GraftAssureDx for FDA review on March 25, 2026 and pointed to the FDA's 150-day De Novo review guidance, while also noting review-clock stops are possible; a clean review would be the clearest near-term re-rating driver, but delay or added data requests would likely pressure shares [#10-K-2026-03-26] [#PR-2026-03-26].
2026-12-31catalystProof of early commercialization traction in transplant testingHigh impact
Management framed 2026 as a transition toward commercialization, with goals including U.S. launch of GraftAssureDx after authorization, U.K./EU regulatory progress, RUO kit sales, broader transplant-center engagement, and heart-transplant R&D funded by the February raise; these are meaningful if executed, but remain management goals rather than booked demand today [#10-K-2026-03-26] [#PR-2026-03-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology